1. Scrip
  2. >>New Products

FDA Tells RegeneRx It Needs 3rd Phase III Trial On RGN-259 For Dry Eye Syndrome

 
• By Sten Stovall

The FDA is requiring an additional RGN-259 Phase III trial to further show efficacy in both signs and symptoms of dry eye in a larger patient population.

Eye
ReGenTree will begin the third Phase III trial, ARISE-3, this year. • Source: Shutterstock

Although the FDA has accepted all safety data from two Phase III trials of dry eye treatment candidate RGN-259, the agency wants the drug's backers to conduct an additional Phase III trial to further demonstrate its efficacy, a requirement that will push back its prospects for approval in treating a condition with high unmet medical need that affects more than 344 million patients globally.

The RGN-259 setback was announced on April 9 by RegeneRx Biopharmaceuticals Inc. and South Korea's GtreeBNT Co

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.